^
Association details:
| Biomarker: | EML4-ALK variant 2 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations
Published date:
08/02/2023
Excerpt:
ORRs were numerically higher with lorlatinib vs crizotinib for EML4::ALK variant 1 (v1; 80.0% vs 50.0%) and variant 2 (v2; 85.7% vs 50.0%), but were similar between the arms for variant 3 (v3; 72.2% vs 73.9%).
DOI:
https://doi.org/10.1016/j.jtho.2023.07.023
